Measurement of the charged current inclusive muon neutrino interaction cross-section on lead using the T2K ND280 electromagnetic calorimeters

This thesis presents an analysis of neutrino interactions using the Electromagnetic Calorimeters (ECals) of the Tokai-to-Kamioka (T2K) off-axis near detector (ND280) as a target using data collected during T2K run 3C. The analysis presented shows the development of a new set of re- construction algorithms which are able to reconstruct multiple tracks which originate from the same neutrino interaction. The output of this reconstruction is used as the basis of a νμ charged current in- clusive selection in the ND280 ECals. The selected events are then used in a simple χ2 fit to extract a T2K flux-averaged νμ charged cur- rent inclusive cross-section on lead, which is measured as ⟨σCC⟩φ = 8.13+1.33 × 10−39 cm2 nucleon−1.Open Acces

Off-axis characterisation of the CERN T10 beam for low momentum proton measurements with a High Pressure Gas Time Projection Chamber

We present studies of proton fluxes in the T10 beamline at CERN. A prototype high pressure gas time projection chamber was exposed to the beam of protons and other particles, using the 0.8 GeV/c momentum setting in T10, in order to make cross section measurements of low energy protons in argon. To explore the energy region comparable to hadrons produced by GeV-scale neutrino interactions at oscillation experiments, i.e. near 0.1 GeV of kinetic energy, methods of moderating the T10 beam were employed: the dual technique of moderating the beam with acrylic blocks and measuring scattered protons off the beam axis was used to decrease the kinetic energy of incident protons, as well aschange the proton/minimum ionising particle (MIP) composition of the incident flux. Measurements of the beam properties were made using time of flight systems upstream and downstream of the TPC. The kinetic energy of protons reaching the TPC was successfully changed from ∼0.3 GeV without moderator blocks to less than 0.1 GeV with four moderator blocks (40 cm path length). The flux of both protons and MIPs off the beam axis was increased. The ratio of protons to MIPs vary as a function of the off-axis angle allowing for possible optimisation of the detector to select the type of required particles. Simulation informed by the time of flight measurements show that with four moderator blocks placed in the beamline, (5.6 ± 0.1) protons with energies below 0.1 GeV per spill traversed the active TPC region. Measurements of the beam composition and energy are presented

Commissioning of a High Pressure Time Projection Chamber with Optical Readout

Measurements of proton-nucleus scattering and high resolution neutrino-nucleus interaction imaging are key to reduce neutrino oscillation systematic uncertainties in future experiments. A High Pressure Time Projection Chamber (HPTPC) prototype has been constructed and operated at Royal Holloway University of London and CERN as a first step in the development of a HPTPC capable of performing these measurements as part of a future long-baseline neutrino oscillation experiment such as the Deep Underground Neutrino Experiment. In this paper we describe the design and operation of the prototype HPTPC with an Argon based gas mixture. We report on the successful hybrid charge and optical readout, using four CCD cameras, of signals from Am-241 sources

DUNE Offline Computing Conceptual Design Report

This document describes the conceptual design for the Offline Software and Computing for the Deep Underground Neutrino Experiment (DUNE). The goals of the experiment include 1) studying neutrino oscillations using a beam of neutrinos sent from Fermilab in Illinois to the Sanford Underground Research Facility (SURF) in Lead, South Dakota, 2) studying astrophysical neutrino sources and rare processes and 3) understanding the physics of neutrino interactions in matter. We describe the development of the computing infrastructure needed to achieve the physics goals of the experiment by storing, cataloging, reconstructing, simulating, and analyzing $\sim$ 30 PB of data/year from DUNE and its prototypes. Rather than prescribing particular algorithms, our goal is to provide resources that are flexible and accessible enough to support creative software solutions and advanced algorithms as HEP computing evolves. We describe the physics objectives, organization, use cases, and proposed technical solutions

A High Pressure Time Projection Chamber with Optical Readout

Measurements of proton-nucleus scattering and high resolution neutrino-nucleus interaction imaging are key to reduce neutrino oscillation systematic uncertainties in future experiments. A High Pressure Time Projection Chamber (HPTPC) prototype has been constructed and operated at Royal Holloway University of London and CERN as a first step in the development of a HPTPC capable of performing these measurements as part of a future long-baseline neutrino oscillation experiment such as the Deep Underground Neutrino Experiment. In this paper we describe the design and operation of the prototype HPTPC with an argon based gas mixture. We report on the successful hybrid charge and optical readout, using four CCD cameras, of signals from Am-241 sources.Comment: 40 pages, 24 figure

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

DUNE: Status and Perspectives

The Deep Underground Neutrino Experiment (DUNE) provides a rich science program with a focus on neutrino oscillations and other beyond the standard model physics. The high-intensity, wide-band neutrino beam will be produced at the Fermi National Accelerator Laboratory (FNAL) and will be directed to the 40~kt liquid argon far detector at the Sanford Underground Research Facility, 1300~km from FNAL. The primary goals of the experiment are to determine the ordering of neutrino masses and to measure the CP violating phase, $\delta_{\textrm{CP}}$. The underground location of the large DUNE far detector and its excellent energy and spatial resolution will allow also for non-accelerator physics programs predicted by grand unified theories, such as nucleon decay or $n$---$\bar{n}$ oscillations. Moreover, DUNE will be sensitive to the electron neutrino flux from a core-collapse supernova, providing valuable information on the phenomenon's underlying mechanisms. This ambitious project requires extensive prototyping and a testing program to guarantee that all parts of the technology are fully understood and well tested. Two such prototypes, in both single phase (ProtoDUNE-SP) and dual phase (ProtoDUNE-DP) technologies, are under construction and will be operated at the CERN Neutrino Platform (NP) starting in 2018

Physics Program of the Short-Baseline Near Detector

SBND (Short-Baseline Near Detector) will be a 112 ton liquid argon TPC neutrino detector located 110 m from the target of the Fermilab Booster Neutrino Beam. SBND, together with the MicroBooNE and ICARUS-T600 detectors at 470 m and 600 m, respectively, make up the Fermilab Short-Baseline Neutrino (SBN) Program. SBN will search for new physics in the neutrino sector by testing the sterile neutrino hypothesis in the 1 eV2 mass squared region with unrivaled sensitivity. SBND will measure the unoscillated beam flavor composition to enable precision searches for neutrino oscillations via both electron neutrino appearance and muon neutrino disappearance in the far detectors. With a data sample of millions of neutrino interactions (both electron and muon neutrinos), SBND will also perform detailed studies of the physics of neutrino-argon interactions, even in rare channels. In this poster the physics program of SBND will be presented